Andy C. Rawstron

Andy C. Rawstron publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Andy C. Rawstron sits on this spectrum.

Andy C. Rawstron D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Andy C. Rawstron sits on this spectrum.

Best Publications

• EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

  J J M van Dongen;L Lhermitte;S Böttcher;J Almeida

  1100
  Citations

• Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

  Andy C Rawstron;Fiona L Bennett;Sheila J M O'Connor;Marwan Kwok

  768
  Citations

• Diagnostic criteria for monoclonal B-cell lymphocytosis.

  Gerald E. Marti;Andy C. Rawstron;Paolo Ghia;Peter Hillmen

  557
  Citations

• Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

  Paul Moreton;Ben Kennedy;Guy Lucas;Michael Leach

  538
  Citations

• International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

  A C Rawstron;N Villamor;M Ritgen;S Böttcher

  493
  Citations

• Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts

  Andy C. Rawstron;Michael J. Green;Anita Kuzmicki;Ben Kennedy

  416
  Citations

• Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

  Andy C. Rawstron;Ben Kennedy;Ben Kennedy;Ben Kennedy;Paul A. S. Evans;Paul A. S. Evans;Paul A. S. Evans;Faith E. Davies;Faith E. Davies;Faith E. Davies

  394
  Citations

• Human peripheral blood B-cell compartments: A crossroad in B-cell traffic†

  M Perez-Andres;B Paiva;W G Nieto;A Caraux

  347
  Citations

• Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

  Roger G. Owen;Robert A. Kyle;Marvin J. Stone;Andy C. Rawstron

  319
  Citations

• Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

  David Dornan;Fiona Bennett;Yvonne Chen;Mark Dennis

  317
  Citations

• Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion

  Andy C. Rawstron;Martin R. Yuille;Julie Fuller;Matthew Cullen

  314
  Citations

• Monoclonal B-cell Lymphocytosis (MBL): Biology, Natural History, and Clinical Management

  Tait D. Shanafelt;Paolo Ghia;Mark C. Lanasa;Ola Landgren

  298
  Citations

• Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage

  A C Rawstron;R G Owen;F E Davies;R J Johnson

  278
  Citations

• Highly Sensitive B Cell Analysis Predicts Response to Rituximab Therapy in Rheumatoid Arthritis

  Shouvik Dass;Andy C. Rawstron;Edward M. Vital;Karen Henshaw

  278
  Citations

• Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

  Andy C. Rawstron;Andy C. Rawstron;Andy C. Rawstron;Faith E. Davies;Faith E. Davies;Faith E. Davies;Ranjit DasGupta;Ranjit DasGupta;Ranjit DasGupta;A. John Ashcroft;A. John Ashcroft;A. John Ashcroft

  277
  Citations

• B cell biomarkers of rituximab responses in systemic lupus erythematosus.

  Edward M. Vital;Shouvik Dass;Maya H. Buch;Karen Henshaw

  273
  Citations

• Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

  Ben Kennedy;Andy Rawstron;Chris Carter;Mary Ryan

  269
  Citations

• Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

  Geoff Hale;Peppy Rebello;Lee R. Brettman;Chris Fegan

  262
  Citations

• Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

  A C Rawstron;A C Rawstron;S Böttcher;R Letestu;N Villamor

  242
  Citations

• A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

  A. C. Rawstron;C. Fazi;A. Agathangelidis;N. Villamor

  214
  Citations